Results 71 to 80 of about 2,105 (152)

Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer

Therapeutic Advances in Urology
Antibody-drug conjugates and bicycle toxin conjugates represent a tremendous advance in drug delivery technology and have shown great promise in the treatment of urothelial cancer.
Chaim Domb, Jorge A. Garcia, Pedro C. Barata, Prateek Mendiratta, Santosh Rao, Jason R. Brown   +5 more
doaj   +1 more source

Cutaneous drug reaction induced by enfortumab-vedotin. [PDF]

CMAJ
Gretschel L, Wetzel E, Mittank-Weidner T.   +2 more
europepmc   +1 more source

Cavitation of Pulmonary Metastases During Enfortumab Vedotin for Metastatic Ureteral Urothelial Carcinoma. [PDF]

IJU Case Rep
Ito F, Kobayashi K, Hayashi G, Kamijo S, Fujita T.   +4 more
europepmc   +1 more source

Real-world use of enfortumab vedotin in metastatic urothelial carcinoma: efficacy, safety, and risk stratification. [PDF]

Ther Adv Urol
Catalano M, Bartoli S, Salfi A, Bonalda M, Della Seta L, Paulet A, Bloise F, Paolieri F, Galli L, Sisani M, Doni L, Perrella A, Antonuzzo L, Roviello G.   +13 more
europepmc   +1 more source

Enfortumab vedotin-related hemorrhagic vesicular eruption managed with dose reduction. [PDF]

JAAD Case Rep
Mueller K, Pei S, Bogner P, Kuraitis D.
europepmc   +1 more source

Nectin-4 PET for predicting enfortumab vedotin dose-response in urothelial carcinoma. [PDF]

Sci Adv
Mishra A, Sharma AK, Gupta K, Banka DS, Johnson BA, Hoffman-Censits J, Huang P, McConkey DJ, Nimmagadda S.   +8 more
europepmc   +1 more source

Case Report: Zinc deficiency as a modifiable risk factor for enfortumab vedotin-induced cutaneous adverse events. [PDF]

Front Oncol
Nishizawa A, Itoh M, Inoue M, Makiguchi M, Koga F.   +4 more
europepmc   +1 more source

Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab: a path to cure? [PDF]

Oncologist
Jang A, Tripathi N, Lanka SM, Kumar HLS, Jain P, Calaway A, Shoag JE, Vince R, Mendiratta P, Rao S, Garcia JA, Brown JR, Koshkin VS, Campbell MT, Singh P, Barata PC.   +15 more
europepmc   +1 more source

First-line enfortumab vedotin-pembrolizumab versus nivolumab plus gemcitabine-cisplatin in metastatic urothelial cancer: a cost-effectiveness study. [PDF]

Front Public Health
Ying H, Fu B.
europepmc   +1 more source

Optimizing enfortumab vedotin plus pembrolizumab therapy. [PDF]

Oncotarget
Karam EA, Céline YC, Prince G, Attieh F, Kourie HR, Kattan J, Nemer E.   +6 more
europepmc   +1 more source